Developer docs
API playgroundTry for free, no card

Search company profiles

Akrikhin

Full company profile

uuid000zyc9

Namestring
Akrikhin
Legal namestring
Akcionernoye obshchestvo «Khimeksko-farmatsevticheskiy kombinat «AKRIKHIN» (АО «АКРИХИН»)
Websiteurl
akrikhin.ru
Company typeenum
Private
Founded yearint
1936
Descriptiontext

Akrikhin (AO AKRIKHIN) is a Russian pharmaceutical manufacturer founded in 1936 and headquartered in Staraya Kupavna, Moscow Oblast, where it operates a single modern, GMP-certified production complex and an in-house R&D center. The company produces more than 200 pharmaceutical preparations spanning dermatology, cardiology, endocrinology, neurology, pediatrics, urology/nephrology, and gynecology, distributed under both proprietary brand names (Akriderm, Akvadetrim, Fitolizin, Komfoderm, Akrivario, etc.) and the МНН-Акрихин generic sub-brand, alongside a growing line of biologically active dietary supplements (BADs).

Its underlying technology is built on GMP-compliant pharmaceutical manufacturing and proprietary formulation capability, including development of polycomponent (combination) drugs and a 50-product R&D pipeline with 10+ commercial launches annually. Akrikhin has shifted R&D investment up roughly sixfold in recent years and is pursuing first-in-class candidates such as a non-hormonal topical for psoriasis and atopic dermatitis. The portfolio is GMP-certified and recognized through the GxP-Profi 2025 program and Eurasian Academy of Proper Practices quality awards.

The company monetizes a diversified domestic revenue base: (1) prescription and OTC generic drug sales through Russian pharmacy chains, independent pharmacies, and online channels such as uTeka.ru; (2) Russian government procurement under the ZhNVLP framework, where over 100 SKUs are listed (roughly 40–50% of the portfolio), providing stable federal and regional demand; and (3) contract manufacturing for third-party pharmaceutical partners using its GMP-certified capacity. The business is exclusively Russian-domestic, privately held, and led by President Denis Chetverikov.

Short descriptiontext

Akrikhin is a Russian pharmaceutical manufacturer founded in 1936 that produces 200+ generic and combination drugs across seven therapeutic areas from a GMP-certified plant in Staraya Kupavna, distributing through pharmacies, government ZhNVLP procurement, and contract manufacturing for domestic partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMoscow, Russia
HQ citystring
Moscow
HQ countrystring
Russia
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, pharmaceutical manufacturing, prescription medicines, OTC medications, dietary supplements
Industry7 codes
PRIMARYHLAIABAL
Generic Hospital & Institutional Products
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Generic Pharmaceuticals
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Generic pharmaceutical sales (prescription and OTC)
TypeOne Time License
Description

Akrikhin generates revenue through the sale of generic pharmaceutical products — both prescription (retsepturnye) and over-the-counter (bezretsepturnye) drugs — across its portfolio of 200+ preparations. Products include branded generics under the МНН-Акрихин label and branded product lines such as Akriderm, Akvadetrim, Fitolizin, Komfoderm, and others. Revenue is distributed across multiple therapeutic areas including dermatology, cardiology, neurology, and endocrinology.

akrikhin.ru
2Government procurement (ЖНВЛП)
TypeOne Time License
Description

A significant share of revenue comes from supplying essential medicines included in the Russian ЖНВЛП (Vital and Essential Medicines list). Approximately 40–50% of the drug portfolio is covered by this list, securing stable government procurement contracts. Over 100 of the 200+ preparations are on ЖНВЛП.

akrikhin.ru
3Contract manufacturing
TypeProfessional Services
Description

Akrikhin offers contract manufacturing services leveraging its GMP-certified production facilities, attracting partners seeking high-quality local production capacity. The company explicitly markets its production capabilities to potential partners via bd@akrikhin.ru.

akrikhin.ru
4BADy (Dietary supplements) sales
TypeOne Time License
Description

Akrikhin manufactures and sells biologically active dietary supplements including Menoril, Normobakt L, SuperOptic, and Fitolizin PRENATAL through pharmacy channels.

akrikhin.ru
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Operations, Technology or R&D, Personnel
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Akrikhin manufactures and sells a portfolio of more than 200 generic and branded pharmaceutical preparations (prescription and OTC) spanning seven therapeutic areas: dermatology, cardiology, vitamin D supplementation, endocrinology, neurology, pediatrics, and cosmetology. More than 100 of these products are on the Russian ZhNVLP (Vital and Essential Medicines) list, securing government procurement contracts. The company also offers GMP-certified contract manufacturing services to other pharmaceutical companies seeking production capacity in Russia.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 10+ new drugs launched into commercial production annually
+4 more records
Product overview1 text field

Akrikhin is a leading Russian pharmaceutical company founded in 1936, operating a GMP-certified manufacturing complex in Staraya Kupavna, Moscow Oblast. The company produces a broad portfolio of over 200 generic and OTC medications organized around seven therapeutic areas: dermatology (led by the Акридерм corticosteroid line and Микозорал antifungal), cardiology (Гипосарт and Капозид antihypertensives, Эспиро eplerenone), endocrinology/diabetology (Ситаглиптин + Метформин combination, Глидиаб, Глимекомб, Fordigliz, Инсудайв insulin products), neurology (Фонтурацетам nootropic, Баклосан muscle relaxant), pediatrics (Бронхо-Ваксом immunostimulant, Динобутин GI gel), urology/nephrology (Фитолизин in paste/capsule/БАД forms, Фитолизин PRENATAL, Фитолизин nefroCAPS), and gynecology (Овипол Клио estrogen, Клиндацин antibiotic). The portfolio is distributed across two main branding tracks: proprietary branded drugs (Acriderm, Akvadetrim, Fitolysin) and the МНН-Акрихин generic sub-brand. The company holds GMP certification and maintains an active R&D pipeline of 50+ drugs, launching 10+ products annually and expanding into innovative drug development including non-hormonal dermatological topicals and CNS therapies.

Product and service32 records
1Akriderm (Акридерм) line
CategoryDermatology pharmaceuticals
Description

Dermatological corticosteroid product line for treating inflammatory and allergic skin conditions, available in cream, ointment, solution, and combination variants (gentamicin, clotrimazole, salicylic acid).

2Akvadetrim (Аквадетрим)
CategoryVitamin D supplementation
Description

Vitamin D3 (cholecalciferol) supplement for preventing and treating vitamin D deficiency, available as oral drops (15,000 IU/ml) and soluble tablets (500/1,000/2,000 IU).

3Azelik (Азелик)
CategoryDermatology pharmaceuticals
Description

Azelaic acid-based topical gel (15%) for treating acne and rosacea.

4Akriol Pro (Акриол Про)
CategoryDermatology pharmaceuticals
Description

Topical anesthetic cream (2.5% lidocaine + 2.5% prilocaine) for skin anesthesia procedures.

5Phytolysin (Фитолизин)
CategoryUrology/Nephrology pharmaceuticals
Description

Herbal diuretic product for treating urinary tract infections and nephrourolithiasis, available as oral paste (100g) and capsules (40 pcs).

6Phytolysin PRENATAL (Фитолизин ПРЕНАТАЛ)
CategoryDietary supplements
Description

Dietary supplement (BAD) variant of Phytolysin formulated for use during pregnancy, supporting kidney and urinary tract function.

7Phytolysin nefroCAPS (Фитолизин нефроКАПС)
CategoryDietary supplements
Description

Dietary supplement (BAD) in capsule form containing dry plant extracts, a source of flavonoids for maintaining normal kidney and urinary tract function.

8Broncho-Vaxom Junior (Бронхо-Ваксом детский)
CategoryPediatric pharmaceuticals
Description

Immunostimulant capsules for children containing bacterial lysates (3.5 mg) to prevent recurrent respiratory tract infections.

9Clindacin (Клиндацин)
CategoryGynecology pharmaceuticals
Description

Antibiotic lincomoside vaginal suppositories (100 mg clindamycin phosphate) for treating bacterial vaginosis.

10Clindovit (Клиндовит)
CategoryDermatology pharmaceuticals
Description

Topical antibiotic gel (1% clindamycin) for treating acne vulgaris.

11Mycosoral (Микозорал)
CategoryDermatology pharmaceuticals
Description

Topical antifungal ointment (2% ketoconazole) for treating skin mycoses, dermatophytosis, candidiasis, pityriasis versicolor, and seborrheic dermatitis.

12Comfoderm (Комфодерм) line
CategoryDermatology pharmaceuticals
Description

Topical methylprednisolone aceponate corticosteroid line for inflammatory skin diseases, with cream, ointment, ceramides-enriched cream (K), and urea-enriched cream (M2) variants.

13Pantoderm (Пангодерм)
CategoryDermatology pharmaceuticals
Description

Tissue repair stimulant cream containing dexpanthenol (5%) for wound healing, burn treatment, skin barrier protection, and nursing/nipple care.

14Ovipol Clio (Овипол Клио)
CategoryGynecology pharmaceuticals
Description

Vaginal estrogen suppositories (0.5 mg estriol) for hormone replacement therapy treating urogenital atrophy, vulvovaginal atrophy, and menopausal symptoms.

15Dinobutin (Динобутин)
CategoryGastroenterology pharmaceuticals
Description

Oral gel (8.9 mg/g trimebutine maleate) for functional GI disorders including IBS, functional dyspepsia, gallbladder dysfunction, and post-cholecystectomy syndrome; indicated for adults and children from age 3.

16Sitagliptin + Metformin combination (Ситаглиптин + Метформин)
CategoryEndocrinology/Diabetology pharmaceuticals
Description

Combined diabetes medication pairing DPP-4 inhibitor sitagliptin with extended-release metformin, unique for the Russian market, launched 2025-2026.

17Espiro (Эспиро)
CategoryCardiology pharmaceuticals
Description

Mineralocorticoid receptor antagonist (25/50 mg eplerenone) for treating heart failure post-myocardial infarction and chronic heart failure (NYHA Class II).

18Fonturacetam-Akrikhin (Фонтурацетам-Акрихин)
CategoryNeurology pharmaceuticals
Description

Nootropic and psychostimulant tablets (100 mg) for treating CNS disorders, memory/cognitive impairment, cerebrovascular insufficiency, obesity, and chronic alcoholism.

19Fordiglif (dapagliflozin generic)
CategoryEndocrinology/Diabetology pharmaceuticals
Description

Generic dapagliflozin drug competing with AstraZeneca's Forxiga for treating type 2 diabetes; right to sell in Russia upheld by Russian Supreme Court in July 2026.

20MNN-Akrikhin (МНН-Акрихин) generic portfolio
CategoryGeneric pharmaceuticals (sub-brand)
Description

Generic drug sub-brand under MNN (international non-proprietary name) branding covering the company's full therapeutic portfolio across dermatology, cardiology, neurology, gynecology, and gastroenterology.

21Giposart (Гипосарт) line
CategoryCardiology pharmaceuticals
Description

Cardiovascular drug line based on candesartan (angiotensin II receptor antagonist) with combination variants: Giposart A (candesartan + amlodipine), Giposart I (candesartan + indapamide), Giposart N (candesartan + hydrochlorothiazide).

22Glidiab / Glidiab MV (Глидиаб / Глидиаб МВ)
CategoryEndocrinology/Diabetology pharmaceuticals
Description

Sulfonylurea oral hypoglycemic agents for type 2 diabetes: Glidiab (gliclazide 80 mg standard release) and Glidiab MV (gliclazide 30 mg modified release).

23Glimecomb (Глимекомб)
CategoryEndocrinology/Diabetology pharmaceuticals
Description

Fixed-dose combination of glimepiride (40 mg) + metformin (500 mg) for type 2 diabetes treatment.

24Insudayv (Инсудайв) / Insudayv Slim (Инсудайв слим)
CategoryEndocrinology/Diabetology pharmaceuticals
Description

Insulin products: Insudayv (0.25/0.5/1 mg/dose solution for injection) and Insudayv Slim (broader dosing range including 1.7 mg and 2.4 mg for improved glycemic control).

25Kapozid (Капозид)
CategoryCardiology pharmaceuticals
Description

Fixed-dose antihypertensive combination: captopril 25 mg + hydrochlorothiazide 50 mg.

26Diaglinid (Диаглинид)
CategoryEndocrinology/Diabetology pharmaceuticals
Description

Meglitinide class oral hypoglycemic agent (repaglinide 1 mg) for type 2 diabetes, stimulating early-phase insulin secretion.

27Zinakoren (Зинакорен)
CategoryCardiology pharmaceuticals
Description

Calcium channel blocker (2.5/10/15/20 mg) for treating cardiovascular conditions.

28Akrivario (Акриварио)
CategoryAntiviral pharmaceuticals
Description

Antiviral drug (50/100/200 mg) for treating viral infections.

29Menoril (Менорил) / Menoril Plus (Менорил плюс)
CategoryDietary supplements
Description

Dietary supplement (BAD) capsules for women's health, providing phytoestrogen support (genistein); Menoril Plus is an enhanced formulation with higher dosage.

30Normobakt L (Нормобакт Л)
CategoryDietary supplements
Description

Probiotic powder for preparing suspension (3g, 10 sachets) containing Lactobacillus rhamnosus for restoring gut microflora.

31SuperOptic (СуперОптик)
CategoryDietary supplements
Description

Dietary supplement (BAD) capsules (850 mg, 60 capsules) for eye health and vision support, containing lutein and other carotenoids.

32Contract manufacturing services
CategoryContract manufacturing services
Description

GMP-certified contract manufacturing services offered to other pharmaceutical companies seeking reliable production capacity in Russia, marketed via bd@akrikhin.ru.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Club of Investors of the Pharmaceutical and Medical Industry (Клуб инвесторов фармацевтической и медицинской промышленности)
Strategic tierMinorTypeOthers
Description

Akrikhin joined the Club of Investors of the Pharmaceutical and Medical Industry, an association created in 2011 to attract private capital to the Russian pharmaceutical and medical industry. The club develops investment climate in healthcare, supports industry projects, strengthens links between investors, manufacturers, scientific and educational organizations, and facilitates best practice exchange. Akrikhin's 90 years of accumulated expertise is expected to strengthen the club's work on pharmaceutical industry projects in Russia.

akrikhin.ru
Strategic tierMinorTypeOthers
Description

Akrikhin was involved in a patent dispute with UK pharma major AstraZeneca over dapagliflozin (Forxiga). The Russian Supreme Court upheld the Intellectual Property Court's ruling in Akrikhin's favor, ordering AstraZeneca to refrain from actions preventing Akrikhin's competing generic drug Fordiglif from being sold in the Russian market. This was a legal dispute, not a commercial partnership.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Slovenian-headquartered generic pharmaceutical manufacturer with significant operations in Russia. Direct competitor in Russian ЖНВЛП tenders and pharmacy retail, but at substantially larger scale and broader European footprint than Akrikhin.

2Sandoz (Novartis)
TypeBroad incumbent
Description

Global generic and biosimilar pharmaceutical company spun out of Novartis, with established Russian commercial presence. Comparable to Akrikhin in generic portfolio breadth and contract manufacturing capabilities, but at a much larger international scale.

3Obolenskoe Pharmaceutical Enterprise
TypeDirect peer
Description

Russian pharmaceutical manufacturer of generic drugs across multiple therapeutic areas. Direct peer to Akrikhin in the domestic Russian generics market and government procurement channels.

TypeDirect peer
Description

Russian pharmaceutical company developing, manufacturing, and marketing branded and generic drugs in CNS, antibacterial, immunology, and urology. Comparable to Akrikhin in its branded-generic strategy and domestic Russian focus.

TypeBroad incumbent
Description

World's largest generic pharmaceutical manufacturer, with active operations in Russia. Comparable to Akrikhin in generic portfolio breadth, but at vastly larger global scale and broader therapeutic reach.

TypeDirect peer
Description

Largest Russian pharmaceutical manufacturer, producing generics, OTC drugs, and biosimilars across cardiovascular, gastroenterology, and metabolic therapy areas. Direct competitor to Akrikhin in ЖНВЛП tenders and Russian pharmacy retail.

7Polysan
TypeDirect peer
Description

Russian pharmaceutical manufacturer specializing in antivirals, immunomodulators, and metabolic products. Comparable to Akrikhin as a domestic producer serving the Russian hospital and pharmacy channels.

TypeDirect peer
Description

Russian pharmaceutical manufacturer producing generic injectables and specialty products, part of the Pharmstandard group. Comparable to Akrikhin in domestic Russian generic manufacturing and government hospital supply.

TypeBroad incumbent
Description

German-headquartered generic pharmaceutical company with an established Russian commercial presence. Competes with Akrikhin across Russian generics and OTC categories, but as a much larger European incumbent with global manufacturing.

10Vertex (Вертекс)
TypeDirect peer
Description

Russian pharmaceutical manufacturer based in Saint Petersburg producing generics and OTC products in dermatology, neurology, gynecology, and respiratory categories. Closely comparable to Akrikhin in therapeutic breadth and domestic Russian generics focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Akrikhin

Generic Pharmaceuticalsakrikhin.ru

Akrikhin is a Russian pharmaceutical manufacturer founded in 1936 that produces 200+ generic and combination drugs across seven therapeutic areas from a GMP-certified plant in Staraya Kupavna, distributing through pharmacies, government ZhNVLP procurement, and contract manufacturing for domestic partners.

What Akrikhin does

Akrikhin (AO AKRIKHIN) is a Russian pharmaceutical manufacturer founded in 1936 and headquartered in Staraya Kupavna, Moscow Oblast, where it operates a single modern, GMP-certified production complex and an in-house R&D center. The company produces more than 200 pharmaceutical preparations spanning dermatology, cardiology, endocrinology, neurology, pediatrics, urology/nephrology, and gynecology, distributed under both proprietary brand names (Akriderm, Akvadetrim, Fitolizin, Komfoderm, Akrivario, etc.) and the МНН-Акрихин generic sub-brand, alongside a growing line of biologically active dietary supplements (BADs).

Its underlying technology is built on GMP-compliant pharmaceutical manufacturing and proprietary formulation capability, including development of polycomponent (combination) drugs and a 50-product R&D pipeline with 10+ commercial launches annually. Akrikhin has shifted R&D investment up roughly sixfold in recent years and is pursuing first-in-class candidates such as a non-hormonal topical for psoriasis and atopic dermatitis. The portfolio is GMP-certified and recognized through the GxP-Profi 2025 program and Eurasian Academy of Proper Practices quality awards.

The company monetizes a diversified domestic revenue base: (1) prescription and OTC generic drug sales through Russian pharmacy chains, independent pharmacies, and online channels such as uTeka.ru; (2) Russian government procurement under the ZhNVLP framework, where over 100 SKUs are listed (roughly 40–50% of the portfolio), providing stable federal and regional demand; and (3) contract manufacturing for third-party pharmaceutical partners using its GMP-certified capacity. The business is exclusively Russian-domestic, privately held, and led by President Denis Chetverikov.

Akrikhin firmographics

Firmographics
Name
Akrikhin
Legal name
Akcionernoye obshchestvo «Khimeksko-farmatsevticheskiy kombinat «AKRIKHIN» (АО «АКРИХИН»)
Website
https://akrikhin.ru
Company type
Private
Founded year
1936
Operating status
Operating
Headcount range
101–250 employees
Short description
Akrikhin is a Russian pharmaceutical manufacturer founded in 1936 that produces 200+ generic and combination drugs across seven therapeutic areas from a GMP-certified plant in Staraya Kupavna, distributing through pharmacies, government ZhNVLP procurement, and contract manufacturing for domestic partners.
Ownership category
akta.pro rank

Akrikhin industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIABAL
Generic Hospital & Institutional Products
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Generic pharmaceuticals
  • Pharmaceutical manufacturing
  • Prescription medicines
  • OTC medications
  • Dietary supplements

Where Akrikhin is headquartered

Location

Headquarters

HQ city
Moscow
HQ country
Russia
HQ region
Europe

Offices2 records

Markets served

Akrikhin business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Technology or R&D, Personnel

Revenue model

  1. Generic pharmaceutical sales (prescription and OTC): Akrikhin generates revenue through the sale of generic pharmaceutical products — both prescription (retsepturnye) and over-the-counter (bezretsepturnye) drugs — across its portfolio of 200+ preparations. Products include branded generics under the МНН-Акрихин label and branded product lines such as Akriderm, Akvadetrim, Fitolizin, Komfoderm, and others. Revenue is distributed across multiple therapeutic areas including dermatology, cardiology, neurology, and endocrinology.
  2. Government procurement (ЖНВЛП): A significant share of revenue comes from supplying essential medicines included in the Russian ЖНВЛП (Vital and Essential Medicines list). Approximately 40–50% of the drug portfolio is covered by this list, securing stable government procurement contracts. Over 100 of the 200+ preparations are on ЖНВЛП.
  3. Contract manufacturing: Akrikhin offers contract manufacturing services leveraging its GMP-certified production facilities, attracting partners seeking high-quality local production capacity. The company explicitly markets its production capabilities to potential partners via bd@akrikhin.ru.
  4. BADy (Dietary supplements) sales: Akrikhin manufactures and sells biologically active dietary supplements including Menoril, Normobakt L, SuperOptic, and Fitolizin PRENATAL through pharmacy channels.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Akrikhin product offering

Product offering

Core offering

Akrikhin manufactures and sells a portfolio of more than 200 generic and branded pharmaceutical preparations (prescription and OTC) spanning seven therapeutic areas: dermatology, cardiology, vitamin D supplementation, endocrinology, neurology, pediatrics, and cosmetology. More than 100 of these products are on the Russian ZhNVLP (Vital and Essential Medicines) list, securing government procurement contracts. The company also offers GMP-certified contract manufacturing services to other pharmaceutical companies seeking production capacity in Russia.

Product overview

Akrikhin is a leading Russian pharmaceutical company founded in 1936, operating a GMP-certified manufacturing complex in Staraya Kupavna, Moscow Oblast. The company produces a broad portfolio of over 200 generic and OTC medications organized around seven therapeutic areas: dermatology (led by the Акридерм corticosteroid line and Микозорал antifungal), cardiology (Гипосарт and Капозид antihypertensives, Эспиро eplerenone), endocrinology/diabetology (Ситаглиптин + Метформин combination, Глидиаб, Глимекомб, Fordigliz, Инсудайв insulin products), neurology (Фонтурацетам nootropic, Баклосан muscle relaxant), pediatrics (Бронхо-Ваксом immunostimulant, Динобутин GI gel), urology/nephrology (Фитолизин in paste/capsule/БАД forms, Фитолизин PRENATAL, Фитолизин nefroCAPS), and gynecology (Овипол Клио estrogen, Клиндацин antibiotic). The portfolio is distributed across two main branding tracks: proprietary branded drugs (Acriderm, Akvadetrim, Fitolysin) and the МНН-Акрихин generic sub-brand. The company holds GMP certification and maintains an active R&D pipeline of 50+ drugs, launching 10+ products annually and expanding into innovative drug development including non-hormonal dermatological topicals and CNS therapies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Akriderm (Акридерм) line Dermatological corticosteroid product line for treating inflammatory and allergic skin conditions, available in cream, ointment, solution, and combination variants (gentamicin, clotrimazole, salicylic acid).
  • Akvadetrim (Аквадетрим) Vitamin D3 (cholecalciferol) supplement for preventing and treating vitamin D deficiency, available as oral drops (15,000 IU/ml) and soluble tablets (500/1,000/2,000 IU).
  • Azelik (Азелик) Azelaic acid-based topical gel (15%) for treating acne and rosacea.
  • Akriol Pro (Акриол Про) Topical anesthetic cream (2.5% lidocaine + 2.5% prilocaine) for skin anesthesia procedures.
  • Phytolysin (Фитолизин) Herbal diuretic product for treating urinary tract infections and nephrourolithiasis, available as oral paste (100g) and capsules (40 pcs).
  • Phytolysin PRENATAL (Фитолизин ПРЕНАТАЛ) Dietary supplement (BAD) variant of Phytolysin formulated for use during pregnancy, supporting kidney and urinary tract function.
  • Phytolysin nefroCAPS (Фитолизин нефроКАПС) Dietary supplement (BAD) in capsule form containing dry plant extracts, a source of flavonoids for maintaining normal kidney and urinary tract function.
  • Broncho-Vaxom Junior (Бронхо-Ваксом детский) Immunostimulant capsules for children containing bacterial lysates (3.5 mg) to prevent recurrent respiratory tract infections.
  • Clindacin (Клиндацин) Antibiotic lincomoside vaginal suppositories (100 mg clindamycin phosphate) for treating bacterial vaginosis.
  • Clindovit (Клиндовит) Topical antibiotic gel (1% clindamycin) for treating acne vulgaris.
  • Mycosoral (Микозорал) Topical antifungal ointment (2% ketoconazole) for treating skin mycoses, dermatophytosis, candidiasis, pityriasis versicolor, and seborrheic dermatitis.
  • Comfoderm (Комфодерм) line Topical methylprednisolone aceponate corticosteroid line for inflammatory skin diseases, with cream, ointment, ceramides-enriched cream (K), and urea-enriched cream (M2) variants.
  • Pantoderm (Пангодерм) Tissue repair stimulant cream containing dexpanthenol (5%) for wound healing, burn treatment, skin barrier protection, and nursing/nipple care.
  • Ovipol Clio (Овипол Клио) Vaginal estrogen suppositories (0.5 mg estriol) for hormone replacement therapy treating urogenital atrophy, vulvovaginal atrophy, and menopausal symptoms.
  • Dinobutin (Динобутин) Oral gel (8.9 mg/g trimebutine maleate) for functional GI disorders including IBS, functional dyspepsia, gallbladder dysfunction, and post-cholecystectomy syndrome; indicated for adults and children from age 3.
  • Sitagliptin + Metformin combination (Ситаглиптин + Метформин) Combined diabetes medication pairing DPP-4 inhibitor sitagliptin with extended-release metformin, unique for the Russian market, launched 2025-2026.
  • Espiro (Эспиро) Mineralocorticoid receptor antagonist (25/50 mg eplerenone) for treating heart failure post-myocardial infarction and chronic heart failure (NYHA Class II).
  • Fonturacetam-Akrikhin (Фонтурацетам-Акрихин) Nootropic and psychostimulant tablets (100 mg) for treating CNS disorders, memory/cognitive impairment, cerebrovascular insufficiency, obesity, and chronic alcoholism.
  • Fordiglif (dapagliflozin generic) Generic dapagliflozin drug competing with AstraZeneca's Forxiga for treating type 2 diabetes; right to sell in Russia upheld by Russian Supreme Court in July 2026.
  • MNN-Akrikhin (МНН-Акрихин) generic portfolio Generic drug sub-brand under MNN (international non-proprietary name) branding covering the company's full therapeutic portfolio across dermatology, cardiology, neurology, gynecology, and gastroenterology.
  • Giposart (Гипосарт) line Cardiovascular drug line based on candesartan (angiotensin II receptor antagonist) with combination variants: Giposart A (candesartan + amlodipine), Giposart I (candesartan + indapamide), Giposart N (candesartan + hydrochlorothiazide).
  • Glidiab / Glidiab MV (Глидиаб / Глидиаб МВ) Sulfonylurea oral hypoglycemic agents for type 2 diabetes: Glidiab (gliclazide 80 mg standard release) and Glidiab MV (gliclazide 30 mg modified release).
  • Glimecomb (Глимекомб) Fixed-dose combination of glimepiride (40 mg) + metformin (500 mg) for type 2 diabetes treatment.
  • Insudayv (Инсудайв) / Insudayv Slim (Инсудайв слим) Insulin products: Insudayv (0.25/0.5/1 mg/dose solution for injection) and Insudayv Slim (broader dosing range including 1.7 mg and 2.4 mg for improved glycemic control).
  • Kapozid (Капозид) Fixed-dose antihypertensive combination: captopril 25 mg + hydrochlorothiazide 50 mg.
  • Diaglinid (Диаглинид) Meglitinide class oral hypoglycemic agent (repaglinide 1 mg) for type 2 diabetes, stimulating early-phase insulin secretion.
  • Zinakoren (Зинакорен) Calcium channel blocker (2.5/10/15/20 mg) for treating cardiovascular conditions.
  • Akrivario (Акриварио) Antiviral drug (50/100/200 mg) for treating viral infections.
  • Menoril (Менорил) / Menoril Plus (Менорил плюс) Dietary supplement (BAD) capsules for women's health, providing phytoestrogen support (genistein); Menoril Plus is an enhanced formulation with higher dosage.
  • Normobakt L (Нормобакт Л) Probiotic powder for preparing suspension (3g, 10 sachets) containing Lactobacillus rhamnosus for restoring gut microflora.
  • SuperOptic (СуперОптик) Dietary supplement (BAD) capsules (850 mg, 60 capsules) for eye health and vision support, containing lutein and other carotenoids.
  • Contract manufacturing services GMP-certified contract manufacturing services offered to other pharmaceutical companies seeking reliable production capacity in Russia, marketed via bd@akrikhin.ru.

Quantifiable outcome

  • 10+ new drugs launched into commercial production annually
  • +4 more outcomes

Companies that use Akrikhin

Customer profile

Segments3 records

Ideal customer profiles3 records

Akrikhin technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

Feature4 records

Akrikhin partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor.

  • Club of Investors of the Pharmaceutical and Medical Industry (Клуб инвесторов фармацевтической и медицинской промышленности)minorOthersAkrikhin joined the Club of Investors of the Pharmaceutical and Medical Industry, an association created in 2011 to attract private capital to the Russian pharmaceutical and medical industry. The club develops investment climate in healthcare, supports industry projects, strengthens links between investors, manufacturers, scientific and educational organizations, and facilitates best practice exchange. Akrikhin's 90 years of accumulated expertise is expected to strengthen the club's work on pharmaceutical industry projects in Russia.
  • AstraZeneca (patent dispute opponent — adversarial, not partnership)minorOthersAkrikhin was involved in a patent dispute with UK pharma major AstraZeneca over dapagliflozin (Forxiga). The Russian Supreme Court upheld the Intellectual Property Court's ruling in Akrikhin's favor, ordering AstraZeneca to refrain from actions preventing Akrikhin's competing generic drug Fordiglif from being sold in the Russian market. This was a legal dispute, not a commercial partnership.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Akrikhin competitors and assessment

Company assessment

Broad incumbents

  • KRKA: Slovenian-headquartered generic pharmaceutical manufacturer with significant operations in Russia. Direct competitor in Russian ЖНВЛП tenders and pharmacy retail, but at substantially larger scale and broader European footprint than Akrikhin.
  • Sandoz (Novartis): Global generic and biosimilar pharmaceutical company spun out of Novartis, with established Russian commercial presence. Comparable to Akrikhin in generic portfolio breadth and contract manufacturing capabilities, but at a much larger international scale.
  • Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer, with active operations in Russia. Comparable to Akrikhin in generic portfolio breadth, but at vastly larger global scale and broader therapeutic reach.
  • STADA Arzneimittel (Russia): German-headquartered generic pharmaceutical company with an established Russian commercial presence. Competes with Akrikhin across Russian generics and OTC categories, but as a much larger European incumbent with global manufacturing.

Direct peers

  • Obolenskoe Pharmaceutical Enterprise: Russian pharmaceutical manufacturer of generic drugs across multiple therapeutic areas. Direct peer to Akrikhin in the domestic Russian generics market and government procurement channels.
  • Valenta Pharm: Russian pharmaceutical company developing, manufacturing, and marketing branded and generic drugs in CNS, antibacterial, immunology, and urology. Comparable to Akrikhin in its branded-generic strategy and domestic Russian focus.
  • Pharmstandard: Largest Russian pharmaceutical manufacturer, producing generics, OTC drugs, and biosimilars across cardiovascular, gastroenterology, and metabolic therapy areas. Direct competitor to Akrikhin in ЖНВЛП tenders and Russian pharmacy retail.
  • Polysan: Russian pharmaceutical manufacturer specializing in antivirals, immunomodulators, and metabolic products. Comparable to Akrikhin as a domestic producer serving the Russian hospital and pharmacy channels.
  • Sotex (SOТЕКС): Russian pharmaceutical manufacturer producing generic injectables and specialty products, part of the Pharmstandard group. Comparable to Akrikhin in domestic Russian generic manufacturing and government hospital supply.
  • Vertex (Вертекс): Russian pharmaceutical manufacturer based in Saint Petersburg producing generics and OTC products in dermatology, neurology, gynecology, and respiratory categories. Closely comparable to Akrikhin in therapeutic breadth and domestic Russian generics focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Akrikhin social profiles

Digital presence

Akrikhin compliance and trust

Trust signal

Compliance2 records

Akrikhin financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Akrikhin leadership team

Management profile

Number of profiles

Profiles3 records

Akrikhin funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Akrikhin M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Akrikhin

What does Akrikhin do?

Akrikhin manufactures and sells a portfolio of more than 200 generic and branded pharmaceutical preparations (prescription and OTC) spanning seven therapeutic areas: dermatology, cardiology, vitamin D supplementation, endocrinology, neurology, pediatrics, and cosmetology. More than 100 of these products are on the Russian ZhNVLP (Vital and Essential Medicines) list, securing government procurement contracts. The company also offers GMP-certified contract manufacturing services to other pharmaceutical companies seeking production capacity in Russia.

Is Akrikhin a public or private company?

Akrikhin is a private company. It is classified as unknown and is currently operating.

When was Akrikhin founded?

Akrikhin was founded in 1936. It employs 101 to 250 people.

Where is Akrikhin based?

Akrikhin is headquartered in Moscow, Russia, in the Europe region.

How does Akrikhin make money?

Four revenue lines are on record. Generic pharmaceutical sales (prescription and OTC) is the primary driver. The others are government procurement (ЖНВЛП), contract manufacturing and BADy (Dietary supplements) sales.

Who are Akrikhin's main competitors?

Broad incumbents on record are KRKA, Sandoz (Novartis), Teva Pharmaceutical Industries and STADA Arzneimittel (Russia). Direct peers are Obolenskoe Pharmaceutical Enterprise, Valenta Pharm, Pharmstandard, Polysan, Sotex (SOТЕКС) and Vertex (Вертекс).

Does Akrikhin have an API?

No public API is recorded for Akrikhin.

What industry is Akrikhin in?

Akrikhin's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAL, Generic Hospital & Institutional Products, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals